Chemotherapy for prostate cancer
Tsushima, T.; Kumon, H.
Nihon Rinsho. Japanese Journal of Clinical Medicine 58 Suppl: 228-236
2000
ISSN/ISBN: 0047-1852 PMID: 11022719 Document Number: 514525
Document emailed within 1 workday
Related Documents
Salminen, E.K.; Sundström, J.; Nikkanen, V. 2006: Palliative chemotherapy with trofosfamide in advanced prostate cancer Anticancer Research 26(1b): 539-542Rosino, A.; Ballester, I.; Tudela, J.án.; González-Billalabeitia, E. 2018: Chemotherapy in metastatic castration resistant prostate cancer Archivos Espanoles de Urologia 71(8): 676-684
Uekado, Y.; Hirano, A.; Inagaki, T.; Hiroi, A.; Watanabe, T. 1995: Combined hormone and chemotherapy for the patients with advanced prostate cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 22(8): 1041-1045
Fujinami, K.; Miura, T.; Takizawa, A.; Osada, Y. 2005: Combination chemotherapy with docetaxel and cisplatin in patients with hormone-refractory prostate cancer Hinyokika Kiyo. Acta Urologica Japonica 51(1): 5-8
Bourlon, M.ía.T.; Mora, M.; Hinojosa-Fano, J.; Martínez-Benitez, B.; Amini, A.; Castillejos-Molina, R.; Glodé, L.M. 2016: Man with Locally Advanced, High-Risk Prostate Cancer Asks about Adding Chemotherapy to his Treatment Oncology 30(1): 94-98
Bejrananda, T.; Pripatnanont, C.; Tanthanuch, M.; Karnjanawanichkul, W. 2016: Oncological Outcome of Docetaxel-Based Chemotherapy for Men with Metastatic Castration-Resistant Prostate Cancer Journal of the Medical Association of Thailand 99(12): 1315-1321
Romppanen, J.; Haapalainen, T.; Punnonen, K.; Penttilä, I. 2002: Serum sialic acid and prostate-specific antigen in differential diagnosis of benign prostate hyperplasia and prostate cancer Anticancer Research 22(1a): 415-420
Murray, N.P.; Aedo, S.óc.; Reyes, E.; Fuentealba, C.; Jacob, O. 2019: Primary circulating prostate cells, age and prostatic volumen predict the presence of prostate cancer in men with indication of a second prostate biopsy Archivos Espanoles de Urologia 72(1): 16-24
Inoue, Y.; Akiyama, M.; Hashine, K.; Sumiyoshi, Y. 1993: Clinical and pathological efficacies of intra-arterial infusion chemotherapy and radiotherapy combined with hormone therapy in prostate cancer Gan to Kagaku Ryoho. Cancer and ChemoTherapy 20(11): 1686-1688
Sun, S.-C.; Zhao, H.; Liu, R.; Wang, B.-L.; Liu, Y.-Q.; Zhao, Y.; Shi, Z.-D. 2017: Expression of long non-coding RNA H19 in prostate cancer and its effect on the proliferation and glycometabolism of human prostate cancer cells Zhonghua Nan Ke Xue 23(2): 120-124
Grosclaude, P.; Menegoz, F.; Schaffer, P.; Macé Lesec'h, J.; Arveux, P.; Le Mab, G.; Soulié, M.; Villers, A. 1997: Prostate cancer screening (II): is prostate cancer a public health problem? Update of incidence and mortality figures in France from 1982 to 1990 Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 7(4): 647-654
Considine, B.; Petrylak, D.P. 2019: Integrating Novel Targets and Precision Medicine into Prostate Cancer Care-Part 1: the Non-Androgen-Targetable Pathways in Castration-Resistant Prostate Cancer Oncology 33(3): 113-118
Ragde, H.; Grado, G.L.; Nadir, B.S. 2001: Brachytherapy for clinically localized prostate cancer: thirteen-year disease-free survival of 769 consecutive prostate cancer patients treated with permanent implants alone Archivos Espanoles de Urologia 54(7): 739-747
Liu, J-he.; Li, H-wei.; Tong, M.; Li, M.; Na, Y-qun. 2004: Genetic risk factors of prostate cancer in Han nationality population in Northern China and a preliminary study of the reason of racial difference in prevalence of prostate cancer Zhonghua Yi Xue Za Zhi 84(5): 364-368
Perrin, P.; François, O.; Maquet, J.H.; Bringeon, G.; Duteil, P.; Devonec, M. 1991: Circulating prostate cancer specific antigens in benign hypertrophy and localized cancer of the prostate Presse Medicale 20(28): 1313-1319
Fourcade, R-Olivier.; Richaud, P.; Coloby, P.; Malavaud, B. 2007: Role of 150 mg bicalutamide in the treatment of prostate cancer: 3rd analysis of the EPC (early prostate cancer) program Progres en Urologie: Journal de l'Association Francaise d'Urologie et de la Societe Francaise d'Urologie 17(4 Suppl. 1): 891-910
Liu, B.-q.; Wu, Y.-d.; Wei, J.-x.; Zhang, T.; Liu, R.-l.; Ma, T.-x. 2007: Expression of prostate cancer antigen-1 in prostate cancer and its clinical significance Zhonghua Nan Ke Xue 13(11): 997-1001
Zhu, X-Dong.; Zheng, A.; Wang, Z-Qian.; Shao, Q. 2018: Prostate Cancer Prevention Trial risk calculator for evaluating the risk of prostate cancer in the high-risk Chinese population Zhonghua Nan Ke Xue 24(2): 142-146
Bostwick, D.G. 1994: Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer American Journal of Clinical Pathology 102(4 Suppl 1): S31-S37
Fornara, P.; Sturm, W.; Fabricius, P.G.; Schmiedt, E. 1987: Clinical relevance of radioimmunologic determination of prostate specific antigen in prostate cancer Der Urologe. Ausg. a 26(3): 158-161